Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer

BACKGROUND: The survival benefit for single-agent anti–epidermal growth factor receptor (egfr) therapy compared with combination therapy with irinotecan in KRAS wildtype (wt) metastatic colorectal cancer (mcrc) patients in the third-line treatment setting is not known. The objective of the present s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kennecke, H., Chen, L., Blanke, C.D., Cheung, W.Y., Schaff, K., Speers, C.
Format: Artigo
Idioma:Inglês
Publicat: Multimed Inc. 2013
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3851344/
https://ncbi.nlm.nih.gov/pubmed/24311948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.20.1600
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars